Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9385318 | 0.87 | ALDH1A1 (0.51) | LMNAHTTMAPTCYP3A4ALDH1A1 | |
| SCHEMBL29559830 | 0.87 | ALDH1A1 (0.51) | LMNAHTTMAPTCYP3A4ALDH1A1 | |
| SCHEMBL9493313 | 0.86 | SIRT6 (0.49) | SIRT6ESRRALMNAHTTAR | |
| SCHEMBL17374957 | 0.85 | ALDH1A1 (0.50) | LMNAHTTMAPTCYP3A4ALDH1A1 | |
| SCHEMBL9651879 | 0.84 | AR (0.54) | LMNAHTTMAPTARCYP3A4 | |
| SCHEMBL3717453 | 0.83 | AR (0.49) | SIRT6LMNAHTTARCYP3A4 | |
| SCHEMBL15495141 | 0.83 | EPHX2 (0.45) | ESRRALMNAMAPTARSMN1; SMN2 | |
| SCHEMBL13012266 | 0.83 | EPHX2 (0.42) | ESRRALMNAHTTMAPTAR | |
| SCHEMBL16580956 | 0.82 | SIRT6 (0.44) | SIRT6ESRRALMNAHTTMAPT | |
| SCHEMBL17672578 | 0.81 | ALDH1A1 (0.47) | SIRT6ESRRALMNAHTTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107793413-B | Pyrimidine heterocyclic compound and preparation method and application thereof | 上海科州药物研发有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-2697207-B1 | 3-(2-ARYL-CYCLOALKENYLMETHYL)-OXAZOLIDIN-2-ONE DERIVATIVES AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2016-12-14 | — | — | EP | disclosed |
| US-9371294-B2 | Cycloalkenyl aryl derivatives for CETP inhibitor | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-04-30 | — | — | US | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-2697207-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141487-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012110860-A1 | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012110860-A1 | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CRYSTALGENOMICS, INC. (KR) | 2012-05-31 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| US-6835745-B2 | Treating or inhibiting osteoporosis or bone demineralization, inflammatory bowel disease, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometriosis, endometrial cardiovascular disease, Alzheimer's disease | WYETH | 2004-12-28 | — | — | US | disclosed |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| US-4879398-A | Process for producing 2,6-disubstituted tyrosine | MONSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | SIRT6 581/4885ESRRA 2698/4885LMNA 800/4885 |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | SIRT6 2403/4885ESRRA 2420/4885LMNA 2263/4885 |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | ESR2, ESR1, GPER1 | SIRT6 2228/4885ESRRA 4/4885LMNA 4745/4885 |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | SIRT6 581/4885ESRRA 2698/4885LMNA 800/4885 |
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CDC7, CDCA2, CDC5L | SIRT6 1890/4885ESRRA 2971/4885LMNA 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.